全文获取类型
收费全文 | 242篇 |
免费 | 20篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 12篇 |
2016年 | 19篇 |
2015年 | 15篇 |
2014年 | 17篇 |
2013年 | 23篇 |
2012年 | 31篇 |
2011年 | 13篇 |
2010年 | 11篇 |
2009年 | 13篇 |
2008年 | 19篇 |
2007年 | 12篇 |
2006年 | 12篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 9篇 |
2002年 | 7篇 |
2001年 | 1篇 |
1998年 | 1篇 |
1995年 | 1篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
1969年 | 1篇 |
1956年 | 1篇 |
排序方式: 共有262条查询结果,搜索用时 62 毫秒
261.
Igor Spasi Milan Ubavi Zorica umarac Maa Todorovi Biljana Vu
kovi 《Journal of Medical Biochemistry》2021,40(3):245
Background: To investigate the influence of lipid metabolism disorders on the risk of deep vein thrombosis. Methods: A total of 200 subjects participated in the study, 100 of whom experienced DVT with or without PTE, and 100 healthy subjects representing the control group. We classified patients and controls in terms of serum concentrations of chylomicrons, LDL, IDL, VLDL, and HDL particles, as those with or without hyperlipoproteinemia and in terms of serum Lp (a) lipoprotein levels, as those with hyperLp (a) lipoproteinemia (serum Lp (a) values >0.3 g/L) and those without hyperLp (a) lipoproteinemia (serum Lp (a) values <0.3 g/L). Based on the modified and supplemented Fredrickson classification, participants with verified existences of hyperlipoproteinemia were classified into subgroups based on the type of hyperlipoproteinemia. Unconditional logistic regression was used to calculate ORs with 95% CIS as a measure of the relative risks for venous thrombosis in participants with hyperlipoproteinemia compared with those without hyperlipoproteinemia. The analysis was adjusted for all potential confounders (age, sex, obesity) related to the functionality of the lipid metabolism, and at the same time, may have an impact on the risk of venous thrombosis. Results: The results of the comparison of the mean values of individual lipid status parameters between the patient group and the control group clearly indicate higher concentrations of total cholesterol (5.93 mmol/L vs. 5.52 mmol/L), total triglycerides (1.58 mmol/L vs. 1.50 mmol/L), and LDL-cholesterol (3.83 mmol/L vs. 3.44 mmol/L) in the patient group relative to the control group, with a statistically significant difference observed only in the case of LDL-cholesterol concentrations. We have found that type IIa hyperlipoproteinemia is associated with a nearly double increased risk for deep vein thrombosis (OR 1.99; Cl 1.01-3.90), while type IIb, IV, or hyperLp (a) lipoproteinemia did not influence the risk (OR 1.22; 95% Cl 0.79-1.84; OR 0.89; 95% Cl 0.52-1.54 OR 1.85; 95% CI 0.84-4.04). Conclusions: Hypercholesterolemia doubles the risk of deep vein thrombosis development. 相似文献
262.
Lazar S Popovic Gorana Matovina-Brko Maja Popovic Milica Popovic Ana Cvetanovic Ivan Nikolic Biljana Kukic Dragana Petrovic 《World journal of stem cells》2021,13(6):503-520
Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated with salvage regimens, and if eligible for aggressive therapy, treatment is continued with high-dose chemotherapy and autologous stem cell transplantation. Current therapy options can cure substantial numbers of patients, however for some it is still an uncurable disease. Numerous new drugs and cell therapies are being investigated for the treatment of relapsed or refractory lymphomas. Different types of immunotherapy options have shown promising results, and some have already become the standard of care. Here, we review immunotherapy options for the treatment of lymphoma and discuss the results, positions, practical aspects, and future directions of different drugs and cellular therapies for the treatment of this disease. 相似文献